62 results about "Uric acid excretion" patented technology

The preservation number of the bacterial strain is CGMCC (China General Microbiological Culture Collection Center) NO.33629, the preservation date of the bacterial strain is February 24, 2025, the preservation classification of the bacterial strain is Lactobacillus sakei, and the preservation unit of the bacterial strain is China General Microbiological Culture Collection Center. The strain provided by the invention can reduce the concentration of blood uric acid, relieve kidney inflammation caused by hyperuricemia, improve the protein level of a kidney uric acid excretion channel and reduce the expression level of uric acid resorption protein.

The invention belongs to the technical field of biochemistry, and particularly relates to a rice residue oligopeptide and application thereof in reducing uric acid, and the amino acid sequence of the rice residue oligopeptide is any one of SEQ ID NO: 3, SEQ ID NO: 9 and SEQ ID NO: 10. The rice residue oligopeptide can realize multi-target simultaneous intervention of multiple links of uric acid metabolism, has the characteristics of inhibiting uric acid generation, promoting uric acid excretion and resisting oxidation, can realize an excellent uric acid reducing effect, and provides a further theoretical basis for deep development of rice processing byproducts.

The invention provides application of indole-3-lactic acid in preparation of uric acid reducing products, and relates to the technical field of medicines. The indole-3-lactic acid is found to have a good blood uric acid reducing effect for the first time, a new uric acid reducing medicine component is provided for health-care food, hyperuricemia and related diseases thereof, and the indole-3-lactic acid is small in renal function damage and is a safe and efficient uric acid reducing functional component. The gout treatment mechanism of the indole-3-lactic acid is mainly realized by relieving the inflammatory response of the organism and improving uric acid excretion, and the indole-3-lactic acid has dual effects, is different from the mechanism of the existing medicine, and has unique innovation.

The invention belongs to the field of biological medicine, and relates to application of an RINL antagonist in prevention and treatment of hyperuricemia. Specifically, the invention provides an application of an RINL gene or an encoding protein thereof, and the RINL gene or the encoding protein thereof: (1) is used as a marker for diagnosis, detection or prognosis of hyperuricemia; (2) preparing a reagent or a kit for diagnosing or detecting hyperuricemia; or (3) the compound is used for preparing a medicine for preventing and / or treating hyperuricemia. The RINL provided by the invention is an important related gene in the occurrence and development process of hyperuricemia, and is also a potential hyperuricemia treatment site. RINL expression is inhibited, and the uric acid excretion capacity of cells and mice is remarkably improved.

The invention discloses a siraitia grosvenorii instant coffee beverage assisting in reducing uric acid and a preparation method thereof, and belongs to the technical field of food based on the theory of homology of medicine and food. The coffee beverage is composed of instant coffee powder, a compound sweetening agent, coconut milk powder, milk powder and composite herbal powder in a specific proportion. The compound herbal powder is composed of poria cocos, peach kernels, dried tangerine or orange peel and momordica grosvenori which are selected from a medicinal and edible substance catalog. The herbal active ingredients and a coffee system are deeply fused by optimizing an extraction process, the dual regulation effects of inhibiting xanthine oxidase and promoting uric acid excretion are synergistically exerted, and the technical contradiction that common caffeine possibly affects uric acid excretion is effectively solved. The zebra fish in-vivo experiment proves that the level of uric acid can be remarkably reduced (Plt: 0.001), the improvement rate is as high as 17.63%, and a safe and effective daily diet intervention scheme is provided for people with hyperuricemia while the coffee flavor and convenience are provided.

The invention discloses application of beta-alanine in preparation of a medicine for preventing and / or treating uric acid metabolic disorder related diseases. The invention provides a theoretical source of beta-alanine for reducing the uric acid level. In the earlier stage, the applicant of the invention adopts non-target metabolome and targeted metabolome data to construct a hyperuricemia prediction model, and Rmcorr correlation analysis shows that high beta-alanine level and low uric acid level have strong correlation. On the other hand, beta-alanine acid is adopted to intervene in a hyperuricemia mouse, it is proved that beta-alanine can reduce the blood uric acid level of the hyperuricemia mouse and promote urine uric acid excretion, and beta-alanine can be used for preventing and / or treating uric acid metabolic disorder related diseases.

The invention provides a combined lactobacillus salivarius YS-UR90 and a preparation method of the combined lactobacillus salivarius YS-UR90. The saliva combined lactobacillus provided by the invention can secrete protease and glycosidase, and the HCT and FLS gene expression levels of the saliva combined lactobacillus are high, so that the saliva combined lactobacillus can promote phenolic acid active ingredients to generate biotransformation during fermentation, and the proportion of chlorogenic acid and the like in fermentation liquor is increased. For example, marine fish oligopeptide and casein phosphopeptides are used as a composite nitrogen source, dandelion powder is used as a functional substrate, and a composite fermentation product obtained through fermentation of saliva and lactobacillus has the effect of promoting uric acid excretion and has a certain protection effect on kidney injury. The compound fermentation product has the effect of improving hyperuricemia mainly by inhibiting XOD activity, increasing serum urea nitrogen level, improving defect expression of uric acid synthesis gene HPRT1, inhibiting expression of uric acid reabsorption URAT1 and GLUT9 genes and improving expression of excretion genes OAT1 and ABCG2.

The invention discloses a marine fish uric acid lowering peptide with kidney protection activity as well as a preparation method and application of the marine fish uric acid lowering peptide. The marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, with kidney protection activity is prepared, and the marine fish uric acid reducing peptide Trp-Gly-Val-Pro-Glu, WGVPE for short, can remarkably reduce the blood uric acid level in a body, promote uric acid excretion and improve pathological damage of the kidney. In addition, the pentapeptide provided by the invention can be used in common food, food additives and functional food for preventing and treating hyperuricemia and kidney injury or health care products or medicines for relieving hyperuricemia and kidney injury, and has a good application prospect.

The present invention belongs to the field of traditional Chinese medicine technology, specifically relating to a traditional Chinese medicine composition and its use for preventing or treating hyperuricemia. The technical problem to be solved by the present invention is to provide a new option for treating hyperuricemia. The technical solution of the present invention is a traditional Chinese medicine composition for preventing or treating hyperuricemia, comprising the following ingredients: thistle, gardenia, bamboo leaves, angelica, lily, corn silk, broccoli seed extract, and eucommia leaves. The traditional Chinese medicine composition of the present invention has the effects of inhibiting uric acid synthesis, promoting uric acid excretion, improving kidney damage, and protecting the liver.

The invention relates to the technical field of marine microorganisms, in particular to application of combined lactobacillus salivarius in preparation of products for improving metabolism of alcohol and uric acid, the combined lactobacillus salivarius NHNK-603 is preserved in the China Center for Type Culture Collection, and the preservation number is CCTCC NO: M 2024416. Experiments show; the NHNK-603 has the effects of inhibiting the growth of klebsiella pneumoniae, inhibiting the production of alcohol, agglutinating the klebsiella pneumoniae, inhibiting the virulence gene of the klebsiella pneumoniae, promoting alcohol metabolism, reducing alcohol damage, tolerating alcohol, degrading uric acid, inhibiting the activity of xanthine oxidase, promoting uric acid excretion, promoting the proliferation of Alistipes indinctus and synthesizing hippuric acid; the thallus biofilm increases the function of colonization on mucoprotein and intestinal epithelial cells, and can be applied to preparation of products for improving metabolism of alcohol and uric acid.

The invention provides a composition for reducing uric acid and relieving gout and a preparation method thereof, and relates to the technical field of products for reducing uric acid and relieving gout. The composition comprises the following raw materials: 18-24 parts of phellinus igniarius, 9-13 parts of sunflower disc small molecule peptide extract, 3-7 parts of corn stigma, 4-6 parts of poria cocos, 2-5 parts of pawpaw, 3-6 parts of liquorice, 2-5 parts of astragalus extract and 3-6 parts of lettuce extract. The preparation method of the sunflower disc small-molecule peptide extract comprises the following steps: carrying out enzymolysis on sunflower disc powder twice, carrying out membrane filtration to obtain a sunflower disc small-molecule peptide solution, reacting the sunflower disc small-molecule peptide solution with chitosan oligosaccharide and transglutaminase, and carrying out freeze drying to obtain the sunflower disc small-molecule peptide extract. Through the proper raw material composition and proportion, the metabolic function can be effectively regulated to promote excretion of uric acid, so that the content of xanthine oxidase and adenosine deaminase in the liver is obviously reduced, the uric acid level is effectively reduced, the intestinal probiotic structure can be stabilized, the immunity is enhanced, the kidney is protected, and the good effects of reducing uric acid and relieving gout are achieved.

The invention discloses a uric acid-reducing and gout-resisting composition as well as a preparation method and application thereof. The composition capable of reducing uric acid and resisting gout comprises oligosaccharide, plant powder, yeast powder, oligopeptide and probiotic powder. The plant powder in the composition has a diuretic effect and can promote purine and uric acid to be discharged along with urine, so that the content of the uric acid is reduced; the yeast powder is introduced to promote dissolution and discharge of purine, so that the content of uric acid is reduced; probiotics are introduced, reproduction of harmful bacteria such as escherichia coli, clostridium perfringens and enterococcus is inhibited, proliferation of the probiotics is promoted, the micro-ecological environment of the intestinal tract is improved, uric acid entering the intestinal tract is decomposed through metabolism, dissolution of the uric acid is promoted, the influence of intestinal flora on uric acid excretion is reduced, and it is ensured that uric acid in the intestinal tract is excreted; the uric acid reducing and gout resisting composition disclosed by the invention has a relatively good protection effect on the liver.

The invention discloses a traditional Chinese medicine composition containing medicinal and edible medicinal materials such as chicory leaves, astragalus membranaceus, pawpaw and mango leaves, a pharmaceutical composition as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition achieves the effect of reducing uric acid through the effects of inhibiting uric acid reabsorption and promoting uric acid excretion, and has an exact treatment effect on hyperuricemia. The medicinal material base source is stable, the medicine is safe and effective, clinical application is flexible, and different dosage forms can be prepared according to needs. The preparation process is stable and controllable and is easy to amplify.

The application discloses application of tomato saponin in preparation of a uric acid reducing composition and belongs to the technical field of biological medicine. The uric acid reducing composition comprises 80-240 parts of tomato saponin, 50-120 parts of momordica charantia saponin, 25-100 parts of fruit and vegetable extract, 10-20 parts of schizonepeta turczanovii extract, 10-20 parts of terminalia catappa leaf extract and 40-100 parts of soluble dietary mixture. Animal experiment verification shows that the composition can effectively reduce blood uric acid level and improve kidney function through the synergistic effect of multi-target points such as inhibition of uric acid synthesis, promotion of uric acid excretion, anti-inflammatory kidney protection and metabolic regulation, and a safe and efficient solution is provided for hyperuricemia.

The invention relates to application of puerarin peptide in preparation of anti-inflammatory and / or uric acid-reducing drugs, and relates to the technical field of drugs. The preparation method of the kudzuvine root peptide comprises the following steps: taking kudzuvine root, extracting to obtain soluble protein, dialyzing to obtain dialyzed protein, performing enzymolysis to obtain crude polypeptide, and purifying to obtain the kudzuvine root peptide. The puerarin peptide is high in purity and strong in activity, can remarkably inhibit inflammatory reaction, reduce the level of inflammatory factors and effectively relieve inflammatory symptoms, and provides a new efficient natural medicine choice for treatment of inflammatory diseases; meanwhile, the pharmaceutical composition can effectively reduce the serum uric acid level of a hyperuricemia animal model, regulate uric acid transport related gene expression to promote uric acid excretion and improve renal functions and histopathologic injury, shows a good uric acid reducing effect, is high in safety and free of obvious toxic and side effects, and is expected to become an innovative medicine for treating hyperuricemia and gout.

The invention discloses a walnut-derived xanthine oxidase inhibitory peptide and application thereof, and belongs to the technical field of bioactive peptide biology. The amino acid sequence of the xanthine oxidase inhibitory peptide provided by the invention is as shown in SEQ ID No. 1. Through in-vitro activity determination, the IC50 value of the inhibitory peptide is 3.34 mg / mL, and it is proved that the inhibitory peptide has high inhibitory activity on xanthine oxidase. Besides, the inhibitory peptide can reduce the levels of creatinine, urea nitrogen, adenosine deaminase, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, regulate the expression of kidney uric acid resorption protein URAT1, uric acid excretion protein GLUT9 and ABCG2, and significantly reduce the generation of uric acid, can be used for inhibiting xanthine oxidase and preventing or improving hyperuricemia, is applied to preparation of drugs for improving hyperuricemia, and has broad application prospects. The medicine takes the active peptide as the only active ingredient or one of the active ingredients, and has a good application prospect.

The invention discloses an application of parabacteroides dieldrii in preparation of a product for treating hyperuricemia. The activity of xanthine oxidase is inhibited through the parabacteroides dieldrii, uric acid related transporters are changed, and damaged organs are protected to play a uric acid reducing effect, so that chronic hyperuricemia is improved. In vitro, the parabacteroides dieldrii can inhibit the activity of xanthine oxidase. On the animal level, the parabacteroides dielsii can relieve liver and kidney injuries caused by hyperuricemia and can repair the injured intestinal barrier at the same time. Therefore, a design thought can be provided for an intestinal flora uric acid reducing preparation, so that a new intestinal flora target is provided for clinical treatment of hyperuricemia. According to the present invention, the activity of xanthine oxidase is inhibited in vitro, the uric acid transporter URAT1 in the kidney is reduced in vivo, the uric acid excretion transporter ABCG2 is increased, and the liver and kidney injury and the intestinal barrier damage caused by hyperuricemia are relieved so as to reduce the serum uric acid level and improve the hyperuricemia;

The invention relates to the field of traditional Chinese medicine, in particular to a traditional Chinese medicine preparation for preventing and treating hyperuricemia, which is prepared from the following raw materials by weight: 5-20g of gynostemma pentaphyllum, 10-20g of selaginella doederleinii hieron, 5-15g of berchemia lineate, 5-15g of parthenocissus parvifolia, 12-15g of lotus leaf, 12-15g of cassia seed, 12-15g of white paeony root and 3-6g of raw liquorice. The traditional Chinese medicine composition has no obvious influence on the normal blood sugar level, has stable hypoglycemic activity when being used by diabetes patients, cannot reduce the normal blood sugar state when being taken, can reduce the uric acid level, protect the kidney, improve the glomerular filtration rate and promote uric acid excretion, and can effectively treat, inhibit or prevent hyperuricemia.

The invention discloses a novel application of a tetrastigma planicaule water extract in preparation of a medicine for preventing or treating hyperuricemia and related metabolic diseases, the treatment effect and action mechanism of the tetrastigma planicaule water extract on HUA are discussed by establishing a PO and HX induced rat HUA model, and the result shows that the tetrastigma planicaule water extract can be used for preparing a medicine for preventing or treating hyperuricemia and related metabolic diseases. The tetrastigma planicaule water extract can reduce the uric acid level in a rat body by adjusting uric acid transporter protein, promote uric acid excretion, remarkably improve liver and kidney injury and inflammatory cell infiltration induced by PO and HX, relieve a series of reactions caused by hyperuricemia and improve the curative effect of hyperuricemia. And a theoretical basis and a clinical basis are provided for new medicines for clinically treating hyperuricemia and related metabolic diseases thereof.

The present invention relates to dihydroquinazolinone compound, a preparation method therefor, and a use thereof. The dihydroquinazolinone compound has an excellent inhibitory effect on GLUT9, can effectively inhibit GLUT9 activity so as to promote uric acid excretion, thereby achieving a uric acid lowering effect, and can be used for treating diseases related to GLUT9 activity or expression. The dihydroquinazolinone compound or a pharmaceutically acceptable salt thereof has no obvious toxicity to organs, can significantly reduce kidney damage caused by hyperuricemia, and alleviates gout symptoms.

The invention relates to the technical field of medicines, in particular to application of ginsenoside in preparation of medicines for improving kidney inflammation and enhancing uric acid excretion. It is found for the first time that ginsenoside Rg2 can reduce systematic and kidney inflammatory reactions by reducing expression levels of inflammatory factors LPS, TNF-alpha and IL-1beta; by down-regulating the expression level of fibrosis marker molecules alpha-SMA and Smad3, the effect of improving HUA-related kidney inflammation and fibrosis is achieved; by up-regulating the expression levels of uric acid transporters OAT1, OAT3 and ABCG2, the active transport and excretion ability of the kidney to uric acid is enhanced. The discovery can generate great influence on research and treatment of relieving hyperuricemia, and has clinical practical value.

The invention relates to application of mannitol in preparation of drugs for reducing uric acid and / or preventing and treating gout kidney. The mass volume percentage of mannitol is 2-5%, and the mannitol in the concentration range can reduce the serum uric acid level by increasing urine uric acid excretion, reduce the uric acid content of the kidney tissue of a gout patient and reduce the serum urea nitrogen and creatinine content at the same time, so that the kidney tissue is protected. The invention further provides a pharmaceutical composition for reducing uric acid and / or preventing and treating gout kidney, which comprises the following components in percentage by mass volume: 2-5% of mannitol and 0.45-0.9% of sodium chloride. The invention provides new application of mannitol, the mannitol has dual effects of reducing the blood uric acid level and protecting the renal function, and a new treatment choice is provided for gout and gout kidney patients.

The application belongs to the technical field of biological medicine engineering, and particularly relates to application of hypoxia-inducible factor-1 alpha as a target in development or screening of a drug for preventing and treating hyperuricemia, and proposes that hypoxia-inducible factor-1 alpha as a target is applied in development or screening of a drug for preventing and treating hyperuricemia, and the drug can ubiquitinate and degrade hypoxia-inducible factor-1 alpha. Hypoxia-inducible factor-1 alpha can act on xanthine oxidase for generating uric acid, promote generation of uric acid, or regulate vascular endothelial growth factor through hypoxia-inducible factor-1 alpha, cause damage to intestinal epithelial cells and renal tubular epithelial cells, and then inhibit expression of uric acid excretion transporter protein ATP binding cassette subfamily G member 2, and reduce excretion of uric acid. Therefore, hyperuricemia can be effectively prevented and treated, side effects are reduced, and the life quality of patients is improved.

The present invention discloses a composition, which comprises mixed extract A and mixed extract B, and the mass ratio of mixed extract A to mixed extract B is 1:4 - 4:1; wherein mixed extract A is prepared from 20 - 40 parts by weight of Phyllanthus emblica, 10 - 30 parts by weight of honeysuckle, 5 - 15 parts by weight of fresh Imperata cylindrica root, and 5 - 15 parts by weight of dandelion; mixed extract B is prepared from 5 - 15 parts by weight of Cassia obtusifolia, 20 - 40 parts by weight of Cynara scolymus, 5 - 15 parts by weight of Lilium brownii, and 10 - 30 parts by weight of Cornus officinalis; when the composition is applied to the preparation of drugs for reducing uric acid and preventing and treating gout, the experimental results show that the composition can significantly inhibit uric acid production, promote uric acid excretion, thereby reducing blood uric acid, and at the same time has the effects of significantly reducing gouty joint swelling, inhibiting joint inflammation and oxidative stress state. In addition, the composition of the present invention is derived from medicinal and edible homologous plant raw materials, and is safe, convenient to eat and has no toxic side effects.

This invention discloses a uric acid-lowering drug composition, which comprises one or more of the following: levocarnitine, levocarnitine derivatives, pharmaceutically acceptable salts of levocarnitine or its derivatives, glucocorticoids, colchicine, nonsteroidal anti-inflammatory drugs, IL-1β inhibitors, drugs that inhibit uric acid production, drugs that promote uric acid excretion, and uricase. The composition has the effects of lowering uric acid, protecting liver and kidney function, and inhibiting leukopenia.

The invention discloses application of taxifolin in preparation of a product for inhibiting expression of a urate transporter, and relates to the technical field of biological medicines. The invention also provides an application of taxifolin in preparation of a product for promoting uric acid excretion and an application of taxifolin in preparation of a product for protecting human renal epithelial cells. The research finds that taxifolin has the effect of protecting human renal epithelial cells and can play a role in promoting uric acid excretion by regulating URAT1. The taxifolin not only has a good URAT1 regulating effect, but also has good safety, and compared with other similar URAT1 inhibitors, the taxifolin has good safety, protects human kidney epithelial cells, and has good application value.

The present invention belongs to the field of drug synthesis, and specifically relates to an alkylamide nuciferine derivative having both uric acid-lowering and kidney-protecting activities, and its preparation method and application. The present invention structurally modifies nuciferine by introducing active groups, thereby improving the biological activity of nuciferine in lowering uric acid. Cell experiments have found that the alkylamide nuciferine derivative prepared by the present invention can inhibit the expression of URAT1 in HK-2 cells, promote uric acid excretion, thereby reducing uric acid levels, which is of great significance for the further development of new uric acid-lowering drugs. The alkylamide nuciferine derivative with uric acid-lowering and kidney-protecting effects provided by the present invention has a simple synthesis method, low raw material price, and novel structure.

The invention belongs to the technical field of biomedical engineering, particularly relates to application of hypoxia-inducible factor-1alpha serving as a target to development or screening of drugs for preventing and treating hyperuricemia, and provides application of hypoxia-inducible factor-1alpha serving as a target to development or screening of drugs for preventing and treating hyperuricemia. The medicine can be used for ubiquitination degradation of hypoxia-inducible factor-1 alpha. The hypoxia inducible factor-1alpha can act on uric acid to generate xanthine oxidase, so that the generation of the uric acid is promoted; or the hypoxia inducible factor-1 alpha is used for regulating and controlling the vascular endothelial growth factor, so that intestinal epithelial cells and renal tubular epithelial cells are damaged, the expression of uric acid excretion transporter ATP binding cassette subfamily G member 2 is inhibited, and uric acid excretion is reduced. Therefore, hyperuricemia can be effectively prevented and treated, side effects are reduced, and the life quality of patients is improved.

The invention relates to a combined medicine of naltrexone or a structural analogue thereof and a URAT1 inhibitor and application of the combined medicine. The combined medicine can effectively reduce uric acid, treat hyperuricemia and treat renal injury or renal fibrosis. The combined medicine combines different action mechanisms of the two medicines, and can inhibit the activity of xanthine oxidase and reduce reabsorption of renal tubules at the same time, so that uric acid production is reduced, uric acid excretion is increased, and a stronger uric acid reducing effect is expected to be achieved; the damage caused by renal tubule dilatation can be improved, the fibrosis progress is relieved, and then the effect of relieving kidney injury is achieved.

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an LXH-2301 pharmaceutical composition and application of the LXH-2301 pharmaceutical composition in preparation of a medicine for treating gout with hyperuricemia. The LXH-2301 pharmaceutical composition disclosed by the invention comprises the following components: (a) LXH-2301 tablets with the specification of 0.5 g / tablet; (b) febuxostat tablets with the specification of 20 mg / tablet; wherein the LXH-2301 tablet is administered three times a day, two tablets are administered each time, the total dosage is 1.0 g, and the LXH-2301 tablet is combined with the febuxostat tablet for use. Patients suitable for the composition need to simultaneously meet the following screening standards: morning urine pHlt; and 6.0. The LXH-2301 pharmaceutical composition provided by the invention is applied to the preparation of medicines for treating gout with hyperuricemia, and the limitation of insufficient curative effect on patients with uric acid poor excretion type gout is solved; the problem of lack of prevention means for uric acid crystallization kidney injury is solved.